FindTrial
Sign In

Response of transarterial chemo embolisation with Bleomycin ,as compared to Symptomatic medical management, in terms of reduction in the size of lesion in patients with giant/symptomatic hepatic hemangioma

Effectiveness of Bleomycin-Lipiodol Transarterial Chemoembolization Therapy in Hepatic Hemangioma: A Pilot Non-Randomised Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094510
Enrollment
20
Registered
2025-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D134- Benign neoplasm of liver

Interventions

Intervention1: Bleomycin lipiodol trans arterial chemo embolisation: Trans arterial chemo embolisation using maximum 30 mg Bleomycin in 5 mL Saline with maximum 20 mL lipiodol, later embolisation with

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 18 years Patients with imaging diagnosis of typical hemangioma of size more than 5 cm or who are symptomatic Patients willing to give consent for the study

Exclusion criteria

Exclusion criteria: Age less than 18 years Pregnant patients Patients with asymptomatic Hepatic Hemangioma measuring less than 5 cm Patients diagnosed with suspected Hemangioma with imaging revealing alternate diagnosis. Patients who have received any form of treatment in past for Hepatic Hemangioma

Design outcomes

Primary

MeasureTime frame
Size reductionTimepoint: 6 months—

Secondary

MeasureTime frame
Symptomatic resolutionTimepoint: 6 months;Procedural complicationsTimepoint: Post procedural period—

Countries

India

Contacts

Public ContactDr Kaushal Jain

All India Institute of Medical Sciences, New Delhi

newhoperajendra@gmail.com9821624353

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026